Jeff Yass’s Eyegate Pharmaceuticals, Inc. Warrants EYEGW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-35,621
| Closed | -$2K | – | 11501 |
|
|
2020
Q2 | $2K | Buy |
35,621
+16,850
| +90% | +$733 | ﹤0.01% | 10018 |
|
|
2020
Q1 | $1K | Sell |
18,771
-1,947
| -9% | -$52 | ﹤0.01% | 10144 |
|
|
2019
Q4 | $1K | Sell |
20,718
-16,574
| -44% | -$559 | ﹤0.01% | 9602 |
|
|
2019
Q3 | $0 | Buy |
37,292
+2,010
| +6% | +$59 | ﹤0.01% | 11153 |
|
|
2019
Q2 | $0 | Buy |
35,282
+20,817
| +144% | +$702 | ﹤0.01% | 11142 |
|
|
2019
Q1 | $0 | Sell |
14,465
-32,179
| -69% | -$1.01K | ﹤0.01% | 10309 |
|
|
2018
Q4 | $1K | Buy |
+46,644
| New | +$2.42K | ﹤0.01% | 8814 |
|
|
2018
Q1 | – | Sell |
-12,900
| Closed | -$2K | – | 10586 |
|
|
2017
Q4 | $2K | Hold |
12,900
| – | – | ﹤0.01% | 9140 |
|
|
2017
Q3 | $2K | Hold |
12,900
| – | – | ﹤0.01% | 8715 |
|
|
2017
Q2 | $1K | Hold |
12,900
| – | – | ﹤0.01% | 9098 |
|
|
2017
Q1 | $2K | Hold |
12,900
| – | – | ﹤0.01% | 8806 |
|
|
2016
Q4 | $4K | Buy |
+12,900
| New | +$5.08K | ﹤0.01% | 9492 |
|
Jeff Yass's EYEGW Position: Q3 2020 in Review
Jeff Yass sold out of Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) in Q3 2020, closing a stake of 35,621 shares — an estimated $2K sold.
Jeff Yass first reported a position in EYEGW in Q4 2016 and held it in 12 quarters. The position peaked at $4K in Q4 2016. 0 funds tracked by Wall St. Rank hold EYEGW as of Q3 2020.
- Jeff Yass reported no remaining Eyegate Pharmaceuticals, Inc. Warrants position as of Q3 2020 after selling out during the quarter.
- Jeff Yass sold 35,621 Eyegate Pharmaceuticals, Inc. Warrants shares in Q3 2020, an estimated $2K.
- Jeff Yass first reported a position in Eyegate Pharmaceuticals, Inc. Warrants in Q4 2016 and held it in 12 quarters.
- Jeff Yass's Eyegate Pharmaceuticals, Inc. Warrants position peaked at $4K in Q4 2016.
- 0 funds tracked by Wall St. Rank held Eyegate Pharmaceuticals, Inc. Warrants as of Q3 2020.
Based on Susquehanna International Group's 13F filing for Q3 2020, filed 16 Nov 2020.